IL319797B1 - שיטה לסינתזה של תרכובת פורואימידאזופירידין, צורה גבישית של תרכובת פורואימידאזופירידין, וצורה גבישית של מלח שלה - Google Patents

שיטה לסינתזה של תרכובת פורואימידאזופירידין, צורה גבישית של תרכובת פורואימידאזופירידין, וצורה גבישית של מלח שלה

Info

Publication number
IL319797B1
IL319797B1 IL319797A IL31979725A IL319797B1 IL 319797 B1 IL319797 B1 IL 319797B1 IL 319797 A IL319797 A IL 319797A IL 31979725 A IL31979725 A IL 31979725A IL 319797 B1 IL319797 B1 IL 319797B1
Authority
IL
Israel
Prior art keywords
furoimidazopyridine
compound
crystal form
salt
synthesis method
Prior art date
Application number
IL319797A
Other languages
English (en)
Other versions
IL319797A (he
Original Assignee
Hangzhou Highlightll Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Highlightll Pharmaceutical Co Ltd filed Critical Hangzhou Highlightll Pharmaceutical Co Ltd
Publication of IL319797A publication Critical patent/IL319797A/he
Publication of IL319797B1 publication Critical patent/IL319797B1/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/147Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL319797A 2019-06-06 2020-04-30 שיטה לסינתזה של תרכובת פורואימידאזופירידין, צורה גבישית של תרכובת פורואימידאזופירידין, וצורה גבישית של מלח שלה IL319797B1 (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910490418 2019-06-06
PCT/CN2020/088121 WO2020244348A1 (zh) 2019-06-06 2020-04-30 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型

Publications (2)

Publication Number Publication Date
IL319797A IL319797A (he) 2025-05-01
IL319797B1 true IL319797B1 (he) 2026-04-01

Family

ID=73652738

Family Applications (2)

Application Number Title Priority Date Filing Date
IL288348A IL288348B2 (he) 2019-06-06 2020-04-30 שיטה לסינתזה של תרכובת פורואימידאזופירידין, צורה גבישית של תרכובת פורואימידאזופירידין, וצורה גבישית של מלח שלה
IL319797A IL319797B1 (he) 2019-06-06 2020-04-30 שיטה לסינתזה של תרכובת פורואימידאזופירידין, צורה גבישית של תרכובת פורואימידאזופירידין, וצורה גבישית של מלח שלה

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL288348A IL288348B2 (he) 2019-06-06 2020-04-30 שיטה לסינתזה של תרכובת פורואימידאזופירידין, צורה גבישית של תרכובת פורואימידאזופירידין, וצורה גבישית של מלח שלה

Country Status (10)

Country Link
US (1) US12195476B2 (he)
EP (3) EP3981771A4 (he)
JP (2) JP7320628B2 (he)
KR (2) KR102785014B1 (he)
CN (2) CN113906035B (he)
AU (1) AU2020289149B2 (he)
BR (1) BR112021024533A2 (he)
IL (2) IL288348B2 (he)
MX (3) MX2021014319A (he)
WO (1) WO2020244348A1 (he)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ751284A (en) 2016-10-03 2022-09-30 Hangzhou Highlightll Pharmaceutical Co Ltd Novel jak1 selective inhibitors and uses thereof
AU2022342095A1 (en) 2021-09-13 2024-06-27 Hangzhou Highlightll Pharmaceutical Co., Ltd Methods of treating cns disorders
CN114213424B (zh) 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3,2-b]并吡啶衍生物的合成方法
WO2025035069A2 (en) * 2023-08-10 2025-02-13 Biohaven Therapeutics Ltd. Process for producing (3s,6r)-6-(cyanomethyl)- tetrahydro-2h-pyran-3-amine
WO2026032213A1 (zh) * 2024-08-08 2026-02-12 普罗思特(南京)生物科技有限公司 取代的三环衍生物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108366994A (zh) * 2016-10-03 2018-08-03 梁从新 新型Jak1选择性抑制剂及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
JP6359546B2 (ja) * 2012-11-01 2018-07-18 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Jak阻害薬としての三環式縮合チオフェン誘導体
BR112016025427A2 (pt) * 2014-04-30 2017-08-15 Incyte Corp processos de preparação de um inibidor de jak1 e formas do mesmo
JP7291077B2 (ja) * 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ.ベー. Jakファミリーのキナーゼの低分子阻害物質

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108366994A (zh) * 2016-10-03 2018-08-03 梁从新 新型Jak1选择性抑制剂及其用途

Also Published As

Publication number Publication date
CN113906035A (zh) 2022-01-07
JP2022543183A (ja) 2022-10-11
CA3142625A1 (en) 2020-12-10
IL288348A (he) 2022-01-01
BR112021024533A2 (pt) 2022-01-18
KR102785014B1 (ko) 2025-03-20
AU2020289149A1 (en) 2022-01-06
MX2024006688A (es) 2024-06-19
CN113906035B (zh) 2023-11-10
US12195476B2 (en) 2025-01-14
JP7320628B2 (ja) 2023-08-03
IL288348B1 (he) 2025-07-01
CN117327083A (zh) 2024-01-02
KR20240100424A (ko) 2024-07-01
IL288348B2 (he) 2025-11-01
MX2021014319A (es) 2022-01-26
EP3981771A4 (en) 2023-03-15
MX2024004146A (es) 2024-04-22
EP4248966A2 (en) 2023-09-27
NZ782816A (en) 2025-02-28
WO2020244348A1 (zh) 2020-12-10
KR20220016955A (ko) 2022-02-10
JP2023089169A (ja) 2023-06-27
EP4248967A3 (en) 2023-10-11
EP4248966A3 (en) 2023-10-11
IL319797A (he) 2025-05-01
AU2020289149B2 (en) 2023-05-11
US20220227777A1 (en) 2022-07-21
EP3981771A1 (en) 2022-04-13
EP4248967A2 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
HUE061482T2 (hu) Szintézismódszer
ZA202007037B (en) Crystal form of c-met inhibitor and salt form thereof and preparation method therefor
EP3912976A4 (en) SALT OF AN EGFR INHIBITOR, CRYSTALLINE FORM AND METHOD FOR PREPARING THEREOF
EP3275883A4 (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
EP3763713A4 (en) CRYSTAL FORM AND SALT FORM OF A PYRIDOIMIDAZOLE COMPOUND AND THE METHOD FOR MANUFACTURING IT
HUE068098T2 (hu) Eljárás eliglusztát és köztitermékei elõállítására
IL288348A (he) שיטה לסינתזה של תרכובת פורואימידאזופירידין, צורה גבישית של תרכובת פורואימידאזופירידין, וצורה גבישית של מלח שלה
PL3909953T3 (pl) Związek soli updacytynibu i sposób jego otrzymywania
IL273974B1 (he) תרכובות הטרוציקליות מותמרות באמין כמעכבי ehmt2, מלחים שלהן ושיטה לסינתיזה שלהם
PT3766884T (pt) Forma cristalina e tipo de sal de composto de triazolopirimidina e método de preparação associado
ZA202102783B (en) Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same
ZA202003581B (en) Crystal form of urat1 inhibitor, and preparation method therefor
IL289231A (he) מלחים של תרכובות, צורות גבישיות שלהם ושימושיהם
ZA201905751B (en) Method for the continuous synthesis of zeolite crystals
PT3725786T (pt) Forma cristalina e forma salina de inibidor de tgf-bri e método de preparação das mesmas
EP3330267A4 (en) Salt of quinazoline derivative or crystal thereof, and method for producing salt of quinazoline derivative or crystal thereof
IL285219A (he) גביש של הרכב diarylthiohydantoin
IL274274A (he) צורת מלח וצורת גביש של תרכובת כמעכב fgfr4 ושיטת הכנה שלהם
GB201903055D0 (en) Method of oligonucleaotide synthesis
IL304419A (he) גבישי מלח
EP3181556A4 (en) Micromolecule compound, method of synthesis and application thereof
GB2603328B (en) Process for the synthesis of elagolix sodium salt and intermediates of said process
KR102623532B9 (ko) 납-금속 화합물 단결정의 개질방법
IL277578A (he) צורות מלח חדשות של מעכבי urat-1
EP3845534A4 (en) SALT FORM AND CRYSTALLINE FORM OF A NEW AZATRICYCLIC COMPOUND AND USE THEREOF